Five notes:
1. The spinal biologics market is estimated at $1.9 billion for 2020, with the U.S. accounting for $504 million.
2. The revised report reduced previously communicated projections due to the economic implications caused by the COVID-19 pandemic.
3. The bone graft market segment is expected to rise at a CAGR of 2.6 percent and reach $1.4 billion by 2027.
4. China is anticipated to see a 5.2 percent CAGR in the spinal biologics market, hitting $457.7 million by the end of the forecast period.
5. Japan, Canada and Germany are highlighted as noteworthy market competitors.
More articles on biologics:
Ohio health system acquires surgery center for $21M
2 Texas health systems suspend surgeries, others don’t
Stryker’s ASC-focused business: 3 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
